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Abstract: Importance: Opioid use disorder and opioid deaths have increased dramatically in young
adults in the US, but the age-related course or precursors to opioid use among young people are not
fully understood. Objective: To document age-related changes in opioid use and study the childhood
antecedents of opioid use by age 30 years in 6 domains of childhood risk: sociodemographic characteristics;
school or peer problems; parental mental illness, drug problems, or legal involvement; substance use;
psychiatric illness; and physical health. Design, setting, and participants: This community-representative
prospective longitudinal cohort study assessed 1252 non-Hispanic White individuals and American Indian
individuals in rural counties in the central Appalachia region of North Carolina from January 1993 to
December 2015. Data were analyzed from January 2019 to January 2020. Exposures: Between ages
9 and 16 years, participants and their parents were interviewed up to 7 times using the Child and
Adolescent Psychiatric Assessment and reported risk factors in 6 risk domains. Main outcomes and
measures: Participants were assessed again at ages 19, 21, 25, and 30 years for nonheroin opioid use
(any and weekly) and heroin use using the structured Young Adult Psychiatric Assessment. Results:
Of 1252 participants, 342 (27%) were American Indian. By age 30 years, 322 participants had used
a nonheroin opioid (24.2%; 95% CI, 21.8-26.5), 155 had used a nonheroin opioid weekly (8.8%; 95%
CI, 7.2-10.3), and 95 had used heroin (6.6%; 95% CI, 5.2-7.9). Childhood risk markers for later opioid
use included male sex, tobacco use, depression, conduct disorder, cannabis use, having peers exhibiting
social deviance, parents with legal involvement, and elevated systemic inflammation. In final models,
childhood tobacco use, depression, and cannabis use were most robustly associated with opioid use in
young adulthood (ages 19 to 30 years). Chronic depression and dysthymia were strongly associated with
any nonheroin opioid use (OR. 5.43; 95% CI, 2.35-12.55 and OR, 7.13; 95% CI, 1.99-25.60, respectively)
and with weekly nonheroin opioid use (OR, 8.89; 95% CI, 3.61-21.93 and OR, 11.51; 95% CI, 3.05-
42.72, respectively). Among young adults with opioid use, those with heroin use had the highest rates
of childhood psychiatric disorders and comorbidities. Conclusions and relevance: Childhood tobacco use
and chronic depression may be associated with impaired reward system functioning, which may increase
young adults’ vulnerability to opioid-associated euphoria. Preventing and treating early substance use
and childhood mental illness may help prevent later opioid use.
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IMPORTANCE Opioid use disorder and opioid deaths have increased dramatically in young
adults in the US, but the age-related course or precursors to opioid use among young people
are not fully understood.
OBJECTIVE To document age-related changes in opioid use and study the childhood
antecedents of opioid use by age 30 years in 6 domains of childhood risk: sociodemographic
characteristics; school or peer problems; parental mental illness, drug problems, or legal
involvement; substance use; psychiatric illness; and physical health.
DESIGN, SETTING, AND PARTICIPANTS This community-representative prospective longitudinal
cohort study assessed 1252 non-Hispanic White individuals and American Indian individuals in
rural counties in the central Appalachia region of North Carolina from January 1993 to
December 2015. Data were analyzed from January 2019 to January 2020.
EXPOSURES Between ages 9 and 16 years, participants and their parents were interviewed up
to 7 times using the Child and Adolescent Psychiatric Assessment and reported risk factors in
6 risk domains.
MAIN OUTCOMES ANDMEASURES Participants were assessed again at ages 19, 21, 25, and 30
years for nonheroin opioid use (any and weekly) and heroin use using the structured Young
Adult Psychiatric Assessment.
RESULTS Of 1252 participants, 342 (27%) were American Indian. By age 30 years, 322
participants had used a nonheroin opioid (24.2%; 95% CI, 21.8-26.5), 155 had used a
nonheroin opioid weekly (8.8%; 95% CI, 7.2-10.3), and 95 had used heroin (6.6%; 95% CI,
5.2-7.9). Childhood risk markers for later opioid use includedmale sex, tobacco use,
depression, conduct disorder, cannabis use, having peers exhibiting social deviance, parents
with legal involvement, and elevated systemic inflammation. In final models, childhood
tobacco use, depression, and cannabis use were most robustly associated with opioid use in
young adulthood (ages 19 to 30 years). Chronic depression and dysthymia were strongly
associated with any nonheroin opioid use (OR. 5.43; 95% CI, 2.35-12.55 and OR, 7.13; 95% CI,
1.99-25.60, respectively) and with weekly nonheroin opioid use (OR, 8.89; 95% CI, 3.61-21.93
and OR, 11.51; 95% CI, 3.05-42.72, respectively). Among young adults with opioid use, those
with heroin use had the highest rates of childhood psychiatric disorders and comorbidities.
CONCLUSIONS AND RELEVANCE Childhood tobacco use and chronic depressionmay be
associated with impaired reward system functioning, whichmay increase young adults’
vulnerability to opioid-associated euphoria. Preventing and treating early substance use and
childhoodmental illness may help prevent later opioid use.
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B
eginning in the late 1990s, when opioids were pre-
scribedwith few restrictions, opioid use in theUS rose
toepidemic levels.1Prescriptionpractices,whichmade
these highly addictive drugs easily accessible through medi-
cal andnonmedical channels,2-5havebeenoverhauled,6,7but
despite someprogress in addressing theopioidepidemic, it re-
mains unclear how young adults became part of this epi-
demic. Young adults typically do not experience age-related
painproblems thatwarrantopioidprescriptions, but their pre-
mature mortality from opioid overdoses has skyrocketed.8-11
This prospective longitudinal study measured childhood ad-
versities in opioid-naive children from ages 9 to 16 years and
examined the age-related course of opioid use and associa-
tions between childhood risk factors (ages 9 to 16 years) and
opioid use in young adulthood (ages 19 to 30 years).




studies. These studies reported that a considerable percentage
of young people have used opioids13; the prevalence of opioid









stance use12,14,20 as associatedwith later opioid use ormisuse.
In addition,medically relevant factors, including injuries, pain
problems, and nonmedical use of prescription opioids, pre-
dicted later opioid use.12,21-23 To our knowledge, no previous
study has examined associations between experiences as-
sessed in childhood and opioid use in young adults. Most lon-
gitudinalanalysesofopioidusebeginin lateadolescence(eg,age
18years in theMonitoring theFuture study),14 relyingon retro-
spective assessments of childhood experiences, whichmay be
affected by forgetting and recall bias.24,25
Ourprospectivelongitudinalcohortstudyspanning20years
examines the prevalence of any and weekly nonheroin opioid
useandanyheroinusefromages9to30years. Italsotestswhich
childhood risk factors are associatedwith later opioiduse.Data
came from White and American Indian participants in the
central Appalachia region of North Carolina, an epicenter of
the opioid crisis.26 American Indian individuals tend to be
understudied27,28 and are considered at high risk of substance
useproblemsinadolescence.29,30Theyalsoexperiencehighrates
of prematuremortality because of drug and alcohol use.31
Methods
Participants
This study drew on the Great Smoky Mountains Study
(GSMS),32which is a longitudinal representative studyof chil-
dren in 11 predominantly rural counties of North Carolina.32
Three cohorts, aged 9, 11, and 13 years, were recruited from a
pool of approximately 12000 children using a 2-stage sam-
pling design (eFigure 1 in the Supplement), resulting in 1420
participants (49% female).32 Potential participants were ran-
domly selected from the population using a household equal
probability design and screened for risk of psychopathology;
those scoring high for risk of psychopathology were over-
sampled and the rest were randomly sampled. American In-
dian children were oversampled to constitute 25% of the
total sample.32-34 The Duke University Medical Center Insti-
tutional Review Board approved the study, and participants
and theirparentsor guardians signed informedconsent forms.
Participants were paid $20 to $100. This report followed the
Strengthening the Reporting of Observational Studies in Epi-
demiology (STROBE) reporting guideline.
Participantsandaparent figure (typically themother) com-
pleted an annual assessment from ages 9 to 16 years (January
1993 toDecember 2000).Only participants responded at ages
19,21,25,and30years (January1999toDecember2015).Analy-
ses focused onWhite and American Indian participants with
1 or more young adult assessments.
Assessment
TheChild andAdolescent PsychiatricAssessment (CAPA)was
used until age 16 years and the Young Adult Psychiatric As-
sessment (YAPA) thereafter.35-38 These structured interviews
were coded by trained interviewers and checked by supervi-
sors. In addition to opioid use and childhood risk factors, the
interviewsassessedsexandrace/ethnicity.Race/ethnicity cod-
ingwasbasedonparent-reporteddata collectedat the first ob-
servation. Options were taken from the US Census. Race/
ethnicity data were collected to study health disparities.
Lifetimenonheroinopioid andheroinusewas assessed at
each interviewbeginning at age 9 years using theCAPA/YAPA
substance use module (2-week test-retest reliability, 0.98).39
Lifetime nonheroin opioid use was assessed by the question,
“Have you tried any other opioids, likemorphine, codeine, or
otherpainkillers?”andquestionsaboutweeklyuse (“Haveyou
used… at least once aweek for amonth ormore?”). At age 30
years, a question about oxycodone usewas incorporated into
Key Points
Question How common is opioid use in the early decades of life,
and which childhood risk factors are associated with opioid use in
young adulthood?
Findings This cohort study assessed opioid use among 1252
non-Hispanic White individuals and American Indian individuals in
rural counties in the central Appalachia region of North Carolina
from January 1993 to December 2015. By age 30 years,
approximately one-quarter of participants had used opioids, and
the findings revealed that childhood tobacco use and depression
were associated with later nonheroin opioid use in general, weekly
nonheroin opioid use, and heroin use.
Meaning Childhood tobacco use and depressionmay be
associated with impaired reward system functioning, whichmay
increase young adults’ vulnerability to opioid-associated euphoria.
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the any nonheroin opioid use variable. Nonheroin opioid use
was assessed in the part of the interview on illegal sub-
stances; therefore, it is likely that our assessment included
primarilynonmedical use.Medical usewasnot assessed sepa-
rately. Lifetime heroin use was assessed with the question,
“Haveyouever triedheroin?”Binaryopioidusevariableswere
coded as 1 for use and 0 for no use for any nonheroin opioid
use, weekly nonheroin opioid use, and any heroin use. These
outcome variables were not mutually exclusive.
We selected childhood risk factors known to be associated
with opioid use or substance use generally, including socio-
demographic risk or family dysfunction; school or peer
problems; parental mental illness, drug problems, or legal in-
volvement; early substance use; and physical health risks
(Table 1). Physical health risks included systemic inflammation
(assessed by C-reactive protein [CRP] level40), which is an ob-
jective biomarker associated with chronic pain and somatic
symptoms41 as well as depression.42 In addition, CAPA inter-
views assessed child symptoms of psychiatric disorders. Child
and parent reports were typically combined using an either/or
rule tocodechildren’sDiagnosticandStatisticalManualofMen-
talDisorders (FourthEdition)diagnosesateachassessment.The
2-week test-retest reliability of CAPA diagnoses is comparable
withotherhighlystructuredchildpsychiatric interviews.39,43The
recall time frame for childhood psychiatric status and risk fac-
tors was generally the previous 3months.39,43
Statistical Analysis
Prevalence estimateswereweightedwith samplingweights to
adjust fordifferential probability of selectionand togeneralize
results to the broader population from which the sample was
drawn. Numbers of observations reported were unweighted.
Childhoodassociationswithadultopioidusewere testedusing
weighted logistic regressionanalyses inSAS/STATsoftwarever-
sion9.4 (IBM). Instep1, childhoodrisk factorswereentered into
models separately, adjusting for control variables (sex, race/
ethnicity, cohort). Product terms between each risk factor and
sex and race/ethnicity, respectively, tested whether associa-
tions varied by sex or race/ethnicity. In step 2, control vari-
ablesandrisk factors fromagivenriskdomainwereentered into
models simultaneously. In step 3, control variables and all sig-
nificant associations from step 2 were entered simultane-
ously, trimming all associations with P ≥ .10. Sandwich-type
variancecorrections44wereapplied toadjust forparameterand
variance effects induced by sampling stratification. P values
were 2-tailed, and significance was set at P < .05. In addition,
we examined odds ratios (ORs) with a size of 2 or more. Attri-




Cumulative Lifetime Prevalence of Opioid Use
FromChildhood to Early Adulthood
There were a total of 1252 non-Black participants with obser-
vations in young adulthood, 342 (27%) of whomwere Ameri-
can Indian.AlthoughBlack childrenparticipated in theGSMS,
this subsamplewas too small (n = 88) for robust tests of race/
ethnicitydifferencesandwasexcluded.Notably,however, their
lifetime prevalence of opioid usewas low: 12.5%of Black par-
ticipants reported any nonheroin opioid use by age 30 years.
The Figure shows the cumulative lifetime estimates, derived
from repeated lifetime assessments of opioid use from ages 9
to 30 years. By age 30 years, 322 participants had used a non-
heroin opioid (24.2%; 95%CI, 21.8-26.5); 155 had used a non-
heroin opioid weekly (8.8%; 95% CI, 7.2-10.3; 35.8% of those
with any opioid use); and 95 had used heroin (6.6%; 95% CI,
5.2-7.9;21.8%of thosewithanyopioiduse).Theoverlapamong
opioid use variables was significant: 78 participants (80.3%)
with lifetime heroin use at age 30 years had used other opi-
oids (52 [42.5%]weekly). In addition, 52 (31.9%) of thosewith
weekly nonheroin opioid use had also used heroin.
The prevalence of opioid use varied by race/ethnicity and
sex (eFigures 2, 3, and 4 in the Supplement). By age 30 years,
male individuals had a higher lifetime prevalence of any opi-
oid use (214 [28.6%]; 95% CI, 25.1-32.1) and heroin use (70
[9.0%]; 95%CI, 6.7-11.2) than female individuals (108 [19.7%];
95%CI, 16.6-22.8 and 25 [4.1%]; 95%CI, 2.6-5.7, respectively)
(OR, 1.63; 95% CI, 1.05-2.53; P = .03; OR, 2.29; 95% CI, 1.0-
5.17; P = .045 for sex differences, respectively). American
Indian individuals reported higher weekly nonheroin opioid
use than White individuals (104 [8.5%]; 95% CI, 11.3-19.1; 51
[14.9%];95%CI,6.9-10.1;OR, 1.89;95%CI, 1.22-2.93,P = .005).
Childhood Risk Factors and Young Adult Opioid Use
The analytic sample was evenly divided by sex (677 [50.3%]
male). The prevalence of childhood risk factors, aggregated
fromages9 to 16years,wasdivided intogroupsaccording tono
lifetimeuseofopioids, anynonheroinopioiduse,weeklynon-
heroinopioiduse, andheroinuse (eTable 1 in theSupplement).
The ORs of the association between each risk factor and opi-
oid use by age 30 years, adjusted for control variables (step 1
of the analytic strategy), are shown in eTable 2 in the
Supplement.
Table 2 shows associations among the risk factors and
opioidoutcomeswhenall risk factorswithinariskdomainwere
entered intoamultivariatemodel simultaneously (step2of the
analytic strategy). Childhood risk factors associated with at
least 2 of 3 opioid outcomes included tobacco use, depressive
disorders, conductdisorders,havingpeersexhibitingsocialde-
viance, parents with legal involvement, and elevated sys-
temic inflammation (high CRP level). Several risk factors, in-
cluding childhood tobacco use, depressive disorders, and
conduct disorders, were associatedwith both nonheroin opi-
oid use and heroin use. The associations did not meaning-
fully vary by sex or race/ethnicity (eTables 3 and 4 in the
Supplement). Theoverall patternof results heldwhenpartici-
pants who had used opioids by age 16 years were removed
(eTable 5 in the Supplement).
In the finalmodels (step3of the analytic strategy), the fol-
lowing childhood risk factors for young adult opioid use
emerged. For any nonheroin opioid use, risk factors included
tobacco use (OR, 3.96; 95% CI, 2.28-6.53), cannabis use (OR,
3.28; 95% CI, 1.73-6.25), depression (OR, 1.82; 95% CI, 0.97-
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3.12), and male sex (OR, 1.52; 95% CI, 0.94-2.45); for weekly
nonheroin opioid use, risk factors included tobacco use (OR,
5.89; 95% CI, 3.13-11.08), depression (OR, 2.59; 95% CI, 1.10-
6.06), high CRP level (OR, 2.25; 95% CI, 1.13-4.48), and peers
exhibiting social deviance (OR, 2.17; 95% CI, 1.16-4.04); for
heroinuse, risk factors includeddepression (OR, 5.54; 95%CI,
Table 1. Definitions and Assessments of Childhood Risk Factors





Child’s family met ≥2 of the following conditions: below the federal poverty line for family
income, parental high school education only, low parental occupational prestige
Family instability Child’s family met ≥2 of the following conditions: single-parent structure, stepparent in
household, divorce, parental separation, change in parent structure
Family dysfunction Child’s family met ≥5 of the following: lax parental supervision, parental overinvolvement,
physical violence between parents, frequent parental arguments, parental apathy,
involvement of the child in parental arguments, current maternal depression, high conflict
between child and parent, parental activities being a source of tension or worry for the child




Expelled from school Child was suspended or expelled from school
Peers exhibiting
social deviance
Child’s friends are often in trouble, disruptive of others, disrespectful to adults, drink alcohol,
steal, or engage in other socially deviant behaviors (assessed during the first 3 waves of data
collection only)
Mostly older friends Most of child’s friends are ≥2 y older than the child
Experienced bullying Child was bullied (eg, mocked, attacked, threatened) by peers at school, by siblings at home,






≥1 Parent had used services for mental health problems during their lifetime (eg, sought
or received treatment, hospitalization, medication)
Parental drug service
use
≥1 Parent had used services for drug or alcohol problems during their lifetime (eg, sought
or received treatment, hospitalization)
Parent with legal
involvement
≥1 Parent had been arrested or prosecuted during their adult life
Child’s early
substance use
Tobacco use Any tobacco use
Alcohol use Any alcohol use
Cannabis use Any cannabis use
Illicit drug use other
than cannabis
Any illicit drug use other than cannabis or opioid use
Child’s psychiatric risks
(DSM-IV diagnoses)
Anxiety disorder Child met DSM-IV diagnostic criteria for ≥1 anxiety disorder: generalized anxiety disorder,
overanxious disorder, social phobia, separation anxiety disorder, simple phobia, panic
disorder, or agoraphobia
Depressive disorder Child met DSM-IV diagnostic criteria for ≥1 depressive disorder: major depressive disorder,
dysthymia, or minor depression (depression not otherwise specified)
Oppositional defiant
disorder
Child met DSM-IV diagnostic criteria for oppositional defiant disorder




Child met DSM-IV diagnostic criteria for attention deficit hyperactivity disorder (assessed
from parent report only)
Psychiatric
comorbidity
Child met criteria for ≥2 DSM-IV psychiatric disorders simultaneously
Child’s physical health
Obesity Child’s body mass index was calculated from weight and height at each assessment;
obesity was coded when the child met US Centers for Disease Control and Prevention criteria
for obesity
Somatic complaints Child experienced frequent and recurrent (ie, at least weekly) headaches, abdominal,
or muscular/joint pain over a minimum of a 3-mo period





C-reactive protein level ≥3 mg/L; data derived from blood spots that were obtained
during each childhood interview
Abbreviation: DSM-IV, Diagnostic and
Statistical Manual of Mental Disorders
(Fourth Edition).
a Tomaximize recall reliability, the
typical recall time frame used in
Great SmokyMountains Study
assessments was the previous 3
months at each assessment.
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1.90-15.63), tobacco use (OR, 3.64; 95%CI, 1.46-9.09), canna-
bis use (OR, 2.82; 95% CI, 1.12-7.10), and male sex (OR, 2.53;
95% CI, 1.04-6.13).
Association of Specific Childhood Depressive Symptoms
and DiagnosesWith Opioid Use
Althoughdepression is a heterogeneous construct, eTable 6 in
the Supplement shows that every depressive symptom, ex-
ceptmotoric agitation or retardation and fatigue or lack of en-
ergy, was associated with weekly nonheroin opioid and any
heroinuse (ORnearor above2.0).Depressedor irritablemood,
chronically low mood, worthlessness or guilt, and low self-
esteemwere associatedwith all opioid outcomes. Anhedonia,
problems thinking ormaking decisions, suicidal ideation, and
insomnia or hypersomnia were associated with both weekly
nonheroin opioid use and any heroin use.
Table 3 shows associations of childhood major depres-
sivedisorder (MDD),minordepression,dysthymia,andchronic
depression with young adult opioid use. By definition, dys-
thymia is more chronic thanMDD orminor depression.45 Re-
sults suggest that childhood dysthymia and chronic depres-
sion aremore strongly associatedwith later nonheroin opioid
use (bothweeklyandany) thanMDDorminordepression.Each
childhood depressive disorder was strongly associated with
heroin use.
Putative Progression FromAny toWeekly Heroin Use
Analyses comparing groupsdefinedbydifferent levels of opi-
oid use are shown in eTables 7 and 8 in the Supplement. Spe-
cifically, we tested associations among childhood risk factors
and weekly nonheroin opioid (vs any nonheroin opioid) use
andheroin (vsweekly nonheroin opioid) use. These compari-
sonsassume that thosewithweeklynonheroinopioidusepro-
gressed from any nonheroin opioid use and that those with
heroinuseprogressed fromweeklynonheroin opioiduse. Pu-
tative progression to weekly nonheroin opioid use was asso-
ciatedwithAmerican Indianethnicity, childhood tobaccouse,
psychiatric disorders, physical health problems, and having
peers exhibiting social deviance. Putative progression from
weeklynonheroinopioiduse toheroinusewasassociatedwith
childhood family instability, psychiatric disorders (eg, con-
duct disorder and attention-deficit/hyperactivity disorder),
school or peer factors, alcohol use, and somatic complaints.
Discussion
Ourcommunity-representative,prospective longitudinal study
first assessed opioid-naive children aged 9 to 13 years. By age
30 years, 1 in 4 individuals (more male individuals than fe-
male individuals) living at the epicenter of the opioid epi-
demichadusednonheroinopioids.Childhood riskmarkers for
later opioid use included male sex, tobacco use, depression,
conduct disorder, cannabis use, having peers exhibiting so-
cialdeviance,parentswith legal involvement,andelevatedsys-
temic inflammation. In final models, childhood tobacco use
anddepression, particularly chronic depression,were among
the key associations of young adult opioid use. Young adults
withheroinusehad complexmental healthhistorieswith the
highest rates of childhood depression and psychiatric comor-
bidity. Putativeprogression fromany toweeklynonheroinopi-
oid use and then heroin use was associated with somewhat
different sets of risk factors. Health factors and both depres-
sive and conduct disorders were associated with progression
fromany toweeklyuse. Family instability, school or peer risk,
and conduct disorder were associated with progression to
heroin use.
Childhood Depression and Later Opioid Use
Co-occurrence of lifetime MDD and adult problematic sub-
stance use46-50 and pathways frommood disorders to opioid
dependence in adults have been documented.51 We add to
these findings by showing that opioid-naive children experi-
encingdepressionare at increased riskof later opioiduse.This
is concerning considering that depressive symptoms among
US children and adolescents have risen to their highest levels
since 1991.52
One possible reason childhood chronic depression in-
creases the risk of later opioid use is self-medication, in-
cluding the use of psychoactive substances, to alleviate
depression.53-56 Opioids may offer a problematic antidote to
depression-related difficulties detecting and experiencing
reward or pleasure, debilitating low moods, and low self-
esteem. First-time use of opioids can induce feelings of eu-
phoria and competence (the name heroin is derived from the
user feeling like a hero). Thesemood-altering propertiesmay,
whether consciously or unconsciously, increase the appeal
of opioids for self-medicating impaired reward system
functioning.57,58 A minority of children with depression and
possibly fewer young adults receive adequate services from
qualifiedmentalhealthspecialists.59-62Evenwhentreated,de-
pression may be undertreated in young people. After the US
Food andDrug Administration’s 2004 black boxwarning, an-
tidepressant prescriptions for adolescents and young adults
declined steeply,63 and even when they are prescribed, anti-
depressants do not necessarily improve rewards-related
functioning.64
Figure. Cumulative Lifetime Prevalence of Opioid Use
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Any heroin use
Error bars indicate 95% CIs.
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Children with chronic depression may also later take
opioids to alleviate the physical symptoms and pain that
often accompany depression.65-67 Depression as a cause
of such symptoms may not be evident and thus these
complaints may lead to unnecessary opioid prescriptions
and first exposure to opioid-associated euphoria.12,57 Con-
sistent with work showing that pain and physical health
problems often precede long-term opioid use in adults, we
found that childhood somatic complaints (and, at the statis-
tical trend level, elevated inflammation and injury) were
associated with progression from any to weekly nonheroin
opioid use.68-71
Table 2. Results FromMultivariateModels That Entered RiskMarkersWithin Each Risk Doma








opioid use Any heroin use
Total, No. 1252 322 155 95
Sociodemographic
and family characteristics
Family low SES 491 (26.7) 0.93 (0.55-1.55) 1.13 (0.53-2.43) 0.73
(0.30-1.80)
Family instability 377 (24.2) 1.46 (0.88-2.42) 0.88 (0.46-1.70) 2.11
(0.86-5.20)
Family dysfunction 214 (13.6) 1.38 (0.76-2.53) 1.41 (0.67-2.96) 0.79
(0.31-2.01)
Maltreatment 503 (31.0) 1.23 (0.74-2.05) 1.46 (0.73-2.92) 1.79
(0.73-4.38)
Child’s school/peer risk
Expelled from school 86 (4.5) 1.43 (0.61-3.36) 1.55 (0.56-4.31) 2.51
(0.86-7.33)c
Peers exhibit social deviance 528 (33.5) 2.38 (1.47-3.86)a 3.93 (2.06-7.51)b 1.46
(0.67-3.18)
Mostly older friends (≥2 y) 220 (12.3) 1.88 (1.06-3.34)b 0.92 (0.43-2.00) 1.13
(0.44-2.90)






642 (48.5) 1.59 (0.98-2.57)c 0.80 (0.42-1.54) 1.88
(0.76-4.64)
Parental drug service use 299 (15.8) 0.86 (0.49-1.51) 1.32 (0.66-2.65) 2.30
(0.89-5.94)c
Parental legal involvement 661 (41.5) 1.91 (1.18-3.08)d 2.65 (1.33-5.29)d 0.68
(0.27-1.75)
Child’s substance use
Tobacco 364 (22.3) 3.82 (2.17-6.72)b 6.64 (3.27-13.46)b 3.91
(1.56-9.83)d
Alcohol 285 (20.2) 1.32 (0.65-2.65) 1.13 (0.46-2.77) 1.41
(0.58-3.43)
Cannabis 208 (12.9) 2.84 (1.37-5.90)d 2.05 (0.78-5.41) 2.22
(0.85-5.78)
Other illicit drug 51 (2.6) 1.36 (0.32-5.83) 0.53 (0.21-1.36) 3.30
(0.89-12.26)c
Child’s psychiatric risk
Anxiety disorders 176 (10.8) 1.11 (0.56-2.22) 0.81 (0.31-2.15) 1.34
(0.48-3.76)
Depressive disorders 128 (8.4) 2.63 (1.22-5.65)a 3.94 (1.49-10.39)d 6.32
(1.94-20.65)b
Oppositional defiant disorder 270 (13.5) 0.97 (0.51-1.85) 1.85 (0.69-4.93) 0.92
(0.37-2.26)
Conduct disorder 166 (8.1) 2.37 (1.27-4.44)d 2.25 (0.88-5.76)c 3.27
(1.32-8.10)a
ADHD 69 (3.5) 0.89 (0.32-2.49) 0.78 (0.26-2.31) 1.20
(0.31-4.57)
Comorbidity: ≥2 diagnosese 247 (12.9) NA NA NA
Child’s physical health
Obesity 464 (28.6) 0.83 (0.50-1.38) 0.69 (0.34-1.39) 0.90
(0.45-1.80)
Somatic complaints 410 (31.2) 1.05 (0.66-1.68) 1.77 (0.97-3.21)c 2.55
(1.16-5.60)a
Injury 541 (42.4) 1.07 (0.68-1.67) 1.56 (0.83-2.91) 1.49
(0.69-3.22)
Elevated systemic inflammation
(CRP level ≥3 mg/L)






MI, mental illness; NA, not applicable;
OR, odds ratio; SES, socioeconomic
status.
a P < .001.
bP < .05.
c P < .10.
dP < .01.
eNot included in multivariate models.
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Childhood Substance Use and Later Opioid Use
Consistent with studies that began in later adolescence or
adulthood,18,49,50,72 our study revealed strong associations
between earlier tobacco use and later opioid use. Several
mechanisms could be at play. First, adolescent nicotine
exposure alters neurodevelopment, changing the develop-
ing brain’s reward circuitry and motivational systems.73-75
This increases opioid-associated reinforcement and
stimulation76,77 and alters opioid metabolism and efficacy,
increasing misuse liability.78 Second, adolescent nicotine
use or dependence comes w ith soc ia l o r hea l th
challenges,76,79,80 including risk of later depression.81-83
Third, nicotine use lowers adolescents’ pain thresholds84
and increases the risk of health problems for which opioids
are often prescribed.85 Fourth, adolescent tobacco use and
cannabis use are gateways to harder drugs.18,72 Adolescents
who smoke typically select friends with similar habits, who
may provide access to harder drugs.86 Finally, unobserved
genetic factors could underlie nicotine and cannabis use,
depression and rewards system impairments, and opioid
use.87
Race/Ethnicity and Opioid Use
American Indian participants showed particularly high rates
of weekly nonheroin opioid use, which could be because of
early initiation of drug use (eg, cannabis).88 Furthermore, in
the region of study, American Indian individuals may have
better health care access than White individuals because of
the Indian Health Services. Easier access combined with
greater need for health care (eg, because of poor cardiometa-
bolic health40,89) may result in increased contact with health
care professionals, who may prescribe opioids.90 Finally,
American Indian individuals older than 18 years in this
sample received cash transfers of approximately $6000 per
year, potentially increasing disposable income for drug
purchases.91
NoUnique Association Between Several Childhood
Risk Factors and Later Opioid Use
Several associations were notably absent. Alcohol use by
age 16 years was not uniquely associated with opioid use
after adjusting for childhood tobacco use and cannabis use.
This is consistent with some50 but not other49 previous
work. It is possible that only problematic or very early alco-
hol use signal risk of later opioid use.14 In addition, no or few
associations emerged between opioid use and childhood
sociodemographic status, maltreatment, family dysfunction,
or anxiety. Previous studies typically measured these risk fac-
tors retrospectively92 or in late adolescence and young
adulthood22,93 and most did not consider depressive disor-
ders, which may mediate associations between select child-
hood risk factors and later opioid use.
Strengths and Limitations
The current study’s prospective longitudinal community-
representative psychiatric-diagnostic design has many
strengths. For example, prospective assessments from age 9
years, including assessments of childhood adversities or rare
instances of substanceuse, address the problemof retrospec-
tive forgetting.24Furthermore, this study is unique in includ-
ing up to 11 repeated opioid use assessments combined with
up to 7 assessments of childhood psychiatric status and
adversities.
This study had limitations. First, we were unable to dis-
tinguish between medical and nonmedical opioid use.
Because nonheroin opioid use was assessed alongside illegal
drugs, we likely primarily assessed nonmedical use. Medical
and nonmedical use are associated, with many young people
initiating nonmedical use following prescribed opioid use.13
Second, the example opioids listed in the CAPA/YAPA do
not exhaustively reflect those on the market. Additionally,
Black individuals were excluded because of low sample size.
Notably, their lifetime prevalence of opioid use was low,
which is consistent with previous work and likely because
of limited access to health care and racial bias in prescribing
patterns.13,94
Conclusions
Opioid-related premature mortality of young adults has
skyrocketed.11 Although prescription practices have
changed, no effective solution for the current epidemic or
promising preventive measures against future opioid crises
are in sight. Our study identified tobacco use and childhood
depression by age 16 years as key risk factors of young adult
opioid use. Each of these is associated with impaired
rewards function, which increases vulnerability to opioid-
associated euphoria. Our findings suggest strong opportuni-
ties for early prevention and intervention, including in pri-
mary care settings.95-97 Known evidence-based prevention
strategies could save lives, especially because mental health
and substance use disorders are associated with opioid
overdoses among the young.98









opioid use Any heroin use
Total, No. 1252 322 155 95
Major depression 33 (2.3) 2.21 (0.76-6.44) 3.41 (0.92-12.59)b 7.56 (1.92-29.73)c
Minor depression 106 (7.4) 2.98 (1.43-6.22)d 4.46 (1.90-10.50)d 7.97 (3.18-19.67)d
Dysthymia 70 (5.2) 5.43 (2.35-12.55)d 8.89 (3.61-21.93)d 8.16 (2.96-22.46)d
Chronic depression
(≥2 y of any type)
28 (2.4) 7.13 (1.99-25.60)c 11.41 (3.05-42.72)d 3.93 (0.77-20.06)b
Abbreviation: OR, odds ratio.
a Independent predictors were
adjusted for sex, race/ethnicity, and
cohort.
bP < .10.
c P < .01.
dP < .001.
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